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Histone deacetylases (HDACs) induce deacetylation of both histone and non-histone
proteins and play a critical role in the modulation of physiological and pathological
gene expression. Pharmacological inhibition of HDAC has been reported to attenuate
progression of renal fibrogenesis in obstructed kidney and reduce cyst formation in
polycystic kidney disease. HDAC inhibitors (HDACis) are also able to ameliorate renal
lesions in diabetes nephropathy, lupus nephritis, aristolochic acid nephropathy, and
transplant nephropathy. The beneficial effects of HDACis are associated with their
anti-fibrosis, anti-inflammation, and immunosuppressant effects. In this review, we
summarize recent advances on the treatment of various chronic kidney diseases with
HDACis in pre-clinical models.
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Introduction
Histone and non-histone protein acetylation has been widely studied in the field of cancer research
(Kwon et al., 2009; Mahalingam et al., 2010; Selinger et al., 2011). Histone acetyltransferases (HATs)
and histone deacetylases (HDACs) can mediate the acetylated/deacetylated states of histones (Bush
and McKinsey, 2010). HATs induce acetylation of histones H3 and H4 on lysine amino groups
(Spencer and Davie, 1999) whereas HDACs remove acetyl groups from the acetylated proteins.
Acetylation of the ε-amino groups of lysine residues in nucleosomal histone tails by HATs is
considered necessary for the chromatin structure to relax, allowing activation of transcriptional
activators and initiation of gene induction. Inhibition of HDACs with HDAC inhibitors (HDACis)
also enhances the deposition of acetylated histones H3 and H4, thereby modifying chromatin
structure and regulating gene transcription (Turner, 1993; Van Lint et al., 1996). In addition,
HDACs are able to catalyze deacetylation of many non-histone proteins, thus, they are also called
lysine deacetylases to describe their functions more precisely (Glozak et al., 2005). HDACis have
been reported to regulate gene transcription positively or negatively in a gene-specific manner
(Marks et al., 2000).
HDACs are divided into four groups, mainly according to the homology of yeast HDACs.
Class I HDACs (HDAC1, 2, 3, and 8) are critically connected with yeast RPD3 gene. Class II
HDACs (HDAC4, 5, 6, 7, 9, and 10) are related to yeast Hda1 gene. Class III HDACs (SIRT1-7)
are homologous to silent information regulator 2 (Sir2) and have no sequence similarity to class I
and II HDACs; these Sir2 proteins, also called sirtuins are unaffected by known class I/II HDACis.
Class IV (HDAC11) has conserved residues in its catalytic regions that are shared by both class I
and II HDACs. Class I and II HDACs need Zn2+ for their enzymatic reaction. Class IV also has a
Zn2+ based reaction mechanism. However, class III HDACs do not require Zn2+ for their catalysis,
but strictly depend on the cofactor NAD+ (Pang and Zhuang, 2010).
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Currently, the expression profiles and distribution of HDACs
in the kidney have not been completely clarified. It has been
documented that class I HDAC isoforms are expressed in the
cortex of developmental kidney, renal fibroblasts, and renal
tubular cells (Pang et al., 2011; Chen and El-Dahr, 2013; Tang
et al., 2013). HDAC5 and 6 have been identified in the renal
tubules (Marumo et al., 2008; Liu et al., 2012b). SIRT1 is
expressed in both renal tubules (Zhou et al., 2013) and fibroblasts
(Ponnusamy et al., 2014) and HDAC11 is expressed in renal
tubules (Kim et al., 2013). HDACs have been shown to be
involved in a variety of cellular functions such as proliferation,
survival, differentiation, and immunological responses (Van
Beneden et al., 2013).
Most functional roles of HDACs are revealed by application
of HDACis, which are classified into four categories according
to chemical structures: hydroxamates (e.g., vorinostat), cyclic
peptides (e.g., romidepsin), aliphatic acids (e.g., phenylbutyrate),
and benzamides (entinostat) (Miller et al., 2003; Marks et al.,
2004; Dokmanovic and Marks, 2005; Ma et al., 2009). HDACis
primarily target the zinc domains to exert the biological effects
through cell cycle arrest, differentiation and apoptosis in a variety
of tumor models (Acharya et al., 2005). Treatment of renal cell
carcinomawithHDACis also resulted in tumor growth inhibition
(Ramakrishnan and Pili, 2013). To date, two HDACis, vorinostat,
and romideps, have been approved by the FDA to treat cutaneous
and peripheral T cell lymphoma. Other 20 different HDACis
have been tested in the clinic (West and Johnstone, 2014). The
common side-effects of HDACis in humans include fatigue,
nausea, and vomiting and resolve upon treatment withdrawal
(Minucci and Pelicci, 2006).
Although the tumor has been the primary target for HDACis,
HDAC inhibition has also shown beneficial effects in some
FIGURE 1 | The mechanisms by which HDACIs attenuate chronic kidney diseases. HDACIs can protect against chronic kidney diseases through multiple
mechanisms as indicated.
non-neoplastic disorders. HDACis are effective in attenuating
the pathogenesis of several forms of chronic kidney disease
and improving renal function. In this article, we highlight the
therapeutic application of HDACis in pre-clinical models of renal
injury and discuss the mechanisms involved (Figure 1).
HDACs in Renal Interstitial Fibrosis
Progression and development of renal injuries ultimately leads
to renal interstitial fibrosis (Neilson, 2006; Wynn, 2008). Kidney
fibrosis is characterized with activation and proliferation of renal
interstitial fibroblasts as well as accumulation of extracellular
matrix (ECM) components. During development of renal
fibrosis, multiple cytokine, and growth factor signaling pathways
are activated and involved in this process. Emerging evidence
indicates that HDACs are also implicated in renal fibrogenesis.
The mechanisms by which HDACs mediates renal fibrogenesis
remain elusive, but may be associated with regulating the
expression of inflammatory and profibrotic genes and activation
of cell signaling pathways that mediate renal fibrosis. In the
earlier studies, Pang et al. (2009) demonstrated that treatment
with trichostatin A (TSA), a pan HDACi that can block both class
I and class II HDACs, attenuates renal fibrosis in a murine model
of unilateral ureteral obstruction (UUO). TSA treatment also
significantly inhibits expression of α-SMA and fibronectin, two
hallmarks of activated fibroblasts (Pang et al., 2009). Moreover,
silencing of HDAC1 or HDAC2 using specific siRNA blocked
renal fibroblast proliferation and reduced phosphorylation of
STAT3 (signal transducer and activator of transcription 3),
a signaling molecule associated with proliferation of renal
fibroblasts and development of renal fibrosis (Pang et al., 2011).
Recently, Manson et al. (2014) demonstrated that TSA treatment
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preserves the expression of Bmp-7 transcription and attenuates
the pathogenesis of renal injury in obstructive nephropathy. As
BMP-7 is a potent anti-fibrotic molecule, restoration of BMP-7
expression by TSA represents another mechanism by which
HDACis protect against chronic kidney injury. In addition,
Marumo et al. (Liu et al., 2013) showed that HDAC inhibition
also alleviates renal fibrosis through suppression of inflammatory
responses in the injured kidney.
Since non-selective blockade of class I and class II HDACs
does not allow elucidation of their individual roles in renal
fibrogenesis, Liu et al. (2013) further examined the effect of
MS-275, a selective class I inhibitor, on UUO injury and renal
interstitial fibroblast activation and proliferation. Administration
of MS-275 inhibited both renal fibroblast activation and
proliferation and attenuated progression of kidney fibrosis.
MS-275 treatment also inhibited UUO-induced production of
TGF-β1 and phosphorylation of Smad3 and EGFR (epidermal
growth factor receptor). These results suggest that specific
blockade of only class I HDAC can inhibit renal fibrogenesis
through a mechanism involved in the inactivation of the
TGF-β1/Smad3 and EGFR signaling pathways. Although there
is no study thus far to compare the pharmacological effect of
TSA and MS-275 on renal fibroblast activation and development
of renal fibrosis, it has been reported that pre-treatment with
either valproic acid, another inhibitor of class I or TSA attenuates
glomerulosclerosis and tubulointerstitial fibrosis to the similar
degree. Delayed administration of these two inhibitors also
showed comparable effects on the inhibition of renal fibrosis
(Van Beneden et al., 2013). Thus, it appears that class I HDACs
play a pre-dominant role in regulating renal fibrogenesis. Class
III HDACs have been implicated in the regulation of renal
fibrosis. It is evident that specific inhibition of SIRT1/2 alleviates
progression of renal fibrogenesis and reduces renal fibroblast
activation (Ponnusamy et al., 2014). Mechanistic studies showed
that blocking SIRT1/2 inhibits activation of epidermal growth
factor receptor (EGFR) and platelet derived growth factor
receptors (PDGFR), two growth factor receptors associated with
renal fibrosis (Chen et al., 2011; Liu et al., 2012a).
Collectively, these studies indicate that HDACs contribute to
renal fibroblast activation and fibrogenesis. Additional studies
are needed to clarify the role of individual HDAC isoforms
in mediating these processes and elucidate the mechanisms
involved in a great detail.
HDACs in Polycystic Kidney Diseases
Autosomal dominant polycystic kidney disease (ADPKD) is
very common hereditary kidney diseases in humans, affecting
1/500 in the United States (Gabow, 1993). In ADPKD patients,
a large number of bilateral kidney cysts displace normal
kidney parenchyma, leading to end-stage renal disease (ESRD).
ADPKD is mainly caused by gene mutations in one of two
genes: PKD1, which accounts for approximately 85–95% of
the cases and PKD2, which affects about 5–15% of the cases
(Peters and Sandkuijl, 1992). ADPKD is characterized by
development of multiple bilateral renal cysts, and increased
renal epithelial cell proliferation and fluid secretion. As the
gene product of PKD2, polycystin-2 (PC2), either alone or in
complex with the gene product of PKD1, polycystin-1 (PC1),
functions as a calcium-permeable cation channel and regulates
intracellular Ca2+ levels, alteration of signaling pathways
regulated by calcium such as cAMP-dependent B-Raf and
ERK (extracellular signal-regulated kinase) activation resulted in
abnormal proliferation of tubule epithelial cells (Yamaguchi et al.,
2006). In addition, activation of many other signaling pathways
and transcription factors such as EGFR and p53 is also involved
in the development and growth of polycystic kidneys (Harris and
Torres, 2014).
Emerging evidence has revealed the regulatory role of HDACs
in the pathogenesis of polycystic kidneys. Xie et al., showed (Xia
et al., 2010) that histone deacetylase 5 (HDAC5) is a target of
polycystin-dependent fluid stress sensing in renal epithelial cells
in mice. Stimulation of polarized epithelial monolayers with fluid
flow induced phosphorylation and nuclear export of HDAC5
whereas dwonregulation of HDAC5 or treatment with TSA
reduced cyst formation in Pkd2−/− mouse embryos. Cao et al.
(2009) demonstrated that TSA treatment can affect both body
curvature and laterality, two pathological changes associated
with cyst formation in zebrafish and block cyst formation in
pkd2 knockdown animals. Treatment with valproic acid (VPA),
a class I specific HDACi, also delays the development of cyst
production and improves renal function in a mouse ADPKD
model. In addition, Fan et al. showed that administration
of TSA in pregnant mice prevented cyst formation in Pkd1
mutant embryonic kidneys (Fan et al., 2012). TSA treatment
can ameliorate p53-induced repression of the PKD1 expression,
Chang et al. (2006) and Thivierge et al. (2006). As EGFR
activation and nuclear translocation of β-catenin are essential
for ADPKD, the role of HDAC6 in regulating these biological
responses was examined. HDAC6 inhibition blocks EGF-induced
β-catenin nuclear localization, leading to inhibition of epithelial
cell proliferation and promotion of EGFR degradation (Li et al.,
2008). These studies suggest that class I/II HDAC activation is
essential for PKD development and that HDACis may be possible
drug treatments for PKD.
A recent study further reveals that SIRT is also involved in the
pathogenesis of ADPKD (Zhou et al., 2013). SIRT1 upregulation
was observed in embryonic and post-natal Pkd1-mutant mouse
renal epithelial cells and tissues whereas double conditional
knockouts of PKD1 and SIRT1 as well as inhibition of
SIRT1 with a pan-sirtuin inhibitor (nicotinamide) or a
SIRT1-specific inhibitor (EX-527) resulted in delayed renal
cyst formation. Silence or inhibition of SIRT1 also reduced
renal epithelial cell proliferation, but potentiated apoptosis.
Further studies show that SIRT1 mediates cystic epithelial
cell proliferation through altering retinoblastoma (RB) protein
acetylation/phosphorylation and promotes their survival via p53
deacetylation. This study elucidates a functional role of SIRT1
in regulating ADPKD and provides a molecular basis for using
SIRT1 inhibitors to interfere with cyst formation (Zhou et al.,
2013).
HDACs in Diabetic Nephropathy
Diabetic nephropathy (DN) is characterized by ECM protein
accumulation in glomerular mesangium and tubulointerstitium
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with thickening of glomerular and tubular basement membranes,
ultimately progressing to glomerulosclerosis and tubulo-
interstitial fibrosis (Mauer et al., 1984). The earliest finding
of renal involvement in DN is glomerular hypertrophy,
which is caused by glomerular hyper-filtration. Although
targeting diverse signaling pathways has been reported to
attenuate the pathogenesis of DN, two animal studies have
demonstrated the inhibitory effect of HDACis on DN. Gilbert
et al. showed that vorinostat administration resulted in
attenuation of renal hypertrophy in rats (Gilbert et al., 2011).
Advani et al. demonstrated that vorinostat was effective in
decreasing albuminuria and mesangial matrix accumulation
in streptozotocin–wild-type mice (Advani et al., 2011). In
vitro, treatment with VPA and SK-7041, two class I-selective
HDACis, can also reduce expression of ECM components in
renal epithelial cells (NRK52-E) (Noh et al., 2009). In addition,
HDAC2 activity was upregulated in the kidneys of strotozotocin
(STZ) induced diabetic rats and db/db mice. Treatment with
N-acetylcysteine, an antioxidant, decreased TGF-β1 mediated
activation of HDAC2 in NRK52-E cells (Noh et al., 2009). These
data suggest that HDACs are required for the development of
DN and that reactive oxygen species may play an essential role in
mediating TGF-β1-induced activation of HDAC2.
EGFR activation has been shown to be implicated in the DN
(Chen et al., 2014; Zhang et al., 2014). To understand whether
EGFR expression is associated with the HDAC activity, Gilbert
et al. (2011) further investigated the effect of vorinostat on
the expression of EGFR in the early stage of diabetes. They
found that daily treatment with vorinostat in diabetic rats for 4
weeks remarkably reduced EGFR expression and subsequently
inhibited kidney growth and glomerular hypertrophy. In
cultured rat proximal tubule cells, treatment with vorinostat
also decreased EGFR expression, concomitant with cellular
proliferation inhibition. Therefore, HDACs may regulate early
DN through activation of the EGFR signaling pathway.
Podocyte damage accelerates the development of DN,
characterized by loss of cytoskeleton protein integrity, such
as nephrin. An early study showed that miR-29a is a
potent regulator that inhibits fibrotic matrix expression in
high glucose–stressed renal proximal tubule cells (Du et al.,
2010). A recent study (Lin et al., 2014) indicated that miR-
29a is protective against diabetes-induced podocyte damage,
glomerular fibrosis and inflammation, and renal dysfunction.
However, HDAC4-dependent H3K9 hypoacetylation counteracts
miR-29a transcription in high glucose–stressed podocytes,
suggesting that HDAC4 may be an important mediator in
diabetic podocytopathy. Indeed, stimulation of podocytes with
high glucose, advanced glycation end products, or transforming
growth factor-β can increase HDAC4 expression and specific
silencing of HDAC4 reduces podocyte injury in streptozotocin-
induced diabetic rats and diabetic db/dbmice (Wang et al., 2014).
Further studies showed that the protective effect of HDAC4
inhibition is associated with prevention of autophagy defects and
suppression of renal inflammation (Wang et al., 2014). Therefore,
HDAC4 is a critical epigenetic mediator in the pathogenesis
of DN, and specific inhibition of HDAC4 could serve as a
therapeutic approach for DN and related renal diseases.
While application of HDACis is effective in the attenuation
of DN, the combination of HDACis with other inhibitors
might have additive or synergistic effects. Although such studies
have not been performed in the DN, the combination of an
ACE inhibitor with a HDACi has been reported to provide a
better renal protection in a mouse model of HIV-associated
nephropathy (Zhong et al., 2013). These two inhibitors can affect
several important pathways involved in kidney inflammation
and fibrosis, such as NF-κB, interleukin-1, TGF-β, mitogen-
activated protein kinase, and apoptosis signaling (Zhong et al.,
2013). Thus, examination of the therapeutic effect of HDACis
in the treatment of DN in combination with other drugs is
warranted.
HDACs in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a very common
autoimmune disease (Alderaan et al., 2015). Two studies have
examined the role of HDACs in the pathogenesis of SLE
in the MRL-lpr/lpr murine model of lupus. Mishra et al.
(2003) demonstrated a remarkable reduction in proteinuria,
glomerulonephritis, and spleen weight after treatment with TSA.
TSA was also effective in the downregulation of IL-12, IFN-γ,
IL-6, and IL-10 expression levels in splenocytes of this model.
Regna et al. showed that HDAC inhibition with ITF2357, a
specific inhibitor of class I and II HDAC, reduces sera and
urinary markers of lupus, and suppresses expression of several
inflammatory cytokines (IL-1β, TNF-α, IL-6, and IFN-γ) and
improves kidney histopathology (Regna et al., 2014). These data
suggest that class I and II HDACs contribute to the development
of lupus and application of HDACis may have therapeutic
benefits in the treatment of SLE.
Aristolochic Acid Nephropathy
Aristolochic acid nephropathy is a progressive renal interstitial
fibrosis, frequently associated with urothelial malignancies
(Debelle et al., 2008). Recently, Novitskaya et al. (2014)
examined the effect of a HDACi, 4-(phenylthio)butanoic acid
(PTBA) analog methyl-4-(phenylthio)butanoate (M4PTB), on
the kidney injury induced by aristolochic acid. They found that
treatment with M4PTB promotes renal recovery and reduces
renal fibrosis after aristolochic acid injury in mice. These
beneficial effects are associated with increased renal tubular
cell proliferation and decreased G2/M arrest of regenerating
renal tubular epithelial cells. Furthermore, M4PTB treatment
decreased peritubular macrophage infiltration and expression of
macrophage chemokines such as CX3Cl1 and CCL2. Since an
increased number of renal epithelial cell arrested at G2/M phase
of cell cycle represents a maladaptive repair process that leads to
renal fibrosis (Yang et al., 2010), class I/II HDACsmay contribute
to the development of CKD after aristolochic acid injury.
HDACs in Transplant Kidney Injury
Calcineurin inhibitors (CNIs) decrease the rate of acute rejection
in renal transplantation patients, but side effects such as
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TABLE 1 | Effects of HDAC inhibitors on experimental kidney disorders.
Disease models HDAC inhibitors Selectivity Effects of HDAC inhibitors Mechanisms References
Renal interstitial
fibrosis
TSA
Sodium valproate
MS-275
TSA, VPA
Sirtinol
HDAC I/II
HDACI
HDACI
HDAC I/II
SIRT1/2
Attenuates renal fibroblast
proliferation, α-SMA, fibronectin
expression
Attenuates macrophage infiltration
and fibrotic changes
Inhibits renal fibroblast activation
Hamperes glomerulosclerosis and
tubulointerstitial fibrosis
Inhibits renal fibroblast activation and
proliferation as well as renal
fibrogenesis
Inhibits STAT3 activation induced by
UUO
Reduces CSF-1 expression induced
by TNF-α in renal tubular cells
Inhibits TGF-β/Smad3 and EGFR
signaling
N/A
Inhibits EGFR and PDGFRβ signaling.
Pang et al., 2009, 2011
Marumo et al., 2010
Liu et al., 2013
Van Beneden et al., 2013
Ponnusamy et al., 2014
Polycystic kidney
diseases
TSA
TSA
TSA, VPA
EX-527
HDAC I/II
HDAC I/II
HDACI/II
SIRT1
Attenuates p53 induced repression of
the PKD1 promoter
Reduces cyst formation
Suppress kidney cyst formation
Delays renal cyst formation
Deacetylates p53 and binds with Sp1
N/A
N/A
Inhibits cystic epithelial cell
proliferation and induces cystic
epithelial cell apoptosis
Van Bodegom et al., 2006
Xia et al., 2010
Cao et al., 2009
Zhou et al., 2013
Diabetic
nephropathy
TSA, VPA,
SK7041
Vorinostat
SAHA
Sodium butyrate
HDAC I/II
HDAC I
HDAC I/II
HDAC I/II
Pan HDAC
inhibitor
Attenuate ECM accumulation and
EMT
Attenuates cellular proliferation, blunts
renal growth, and glomerular
hypertrophy
Decreases albuminuria, mesangial
collagen IV deposition, and
oxidative-nitrosative stress
Improves renal function
Suppresses TGF-β1 induced HDAC2
activation
Downregulates EGFR expression
Reduces eNOS expression in mouse
kidneys and in cultured human
umbilical vein endothelial cells
Inhibits apoptosis and DNA damage
Noh et al., 2009
Gilbert et al., 2011
Advani et al., 2011
Khan and Jena, 2014
Lupus nephritis TSA, SAHA
ITF2357
HDAC I/II
HDAC I/II
Reduces proteinuria,
glomerulonephritis and spleen weight
Improves kidney histopathology
Downregulates IL-12, IFN-γ, IL-6, and
IL-10 expression
Suppresses expression of IL-1β,
TNF-α, IL-6, and IFN-γ
Mishra et al., 2003
Regna et al., 2014
Aristolochic acid
nephropathy
PTBAs Pan HDAC
inhibitor
Accelerate recovery and reduce
post-injury fibrosis
Decrease G2/M arrest and reduce
macrophage infiltration
Novitskaya et al., 2014
Transplant kidney
injury
FR276457 Pan HDAC
inhibitor
Prolongs allograft survival Suppresses mononuclear cell
infiltration and vasculitis, and inhibits
the proliferation of Jurkat cells by
targeting activity of NF-κB.
Kinugasa et al., 2009
CSF-1, colony stimulating factor 1; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; PTBA, 4-(phenylthio)butanoic acid; SAHA, suberoylanilide hydroxamic acid;
STAT3, signal transducer and activator of transcription 3; α-SMA, α-smooth muscle actin; TSA, Trichostatin A; VPA, valproic acid; TNF-α, tumor necrosis factor; TGF-β, transforming
growth factor-β.
nephrotoxicity, neurotoxicity, and diabetogenicity (Shapiro
et al., 1994), limit application of these drugs. Furthermore, CNIs
are less effective in preventing chronic allograft rejection and the
promotion of tolerance. Therefore, it is essential to search for
novel and safer immunosuppressants with different mechanisms.
Histone deacetylases (HDACs) are known to mediate
transcription of genes that trigger immunological responses
(Johnstone, 2002; Remiszewski, 2002). Studies examining
the effect of HDACis on kidney injury after transplantation
suggest that HDACis can initiate immunosuppression and
prolong graft survival (Takahashi et al., 1996; Mishra et al.,
2001). Edens et al. showed that HDACis were able to induce
antigen-specific energy in lymphocytes (Edens et al., 2006). Tao
et al. reported that HDAC inhibition improved the generation
and function of regulatory T cells (Tao and Hancock, 2007).
Moreover, Kinugasa et al. demonstrated that FR276457 had a
remarkable immunosuppressive effect in a heterotopic cardiac
transplant rat model (Kinugasa et al., 2008) and was able
to prolong the median survival time (MST) in transplanted
grafts in a canine renal transplant model. The combination of
FR276457 with tacrolimus can also prevent allograft rejection.
Histopathological analysis indicated that FR276457 suppressed
mononuclear cell infiltration and vasculitis. Therefore, HDAC
inhibition may prolong the MST in transplanted grafts when
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administered alone or combined with other immunosuppressive
agents.
Conclusion and Future Directions
Numerous studies have shown that treatment with HDACis is
able to inhibit activation and proliferation of cultured renal
interstitial fibroblasts and attenuate renal fibrosis in animal
models. HDAC inhibition is also beneficial for other chronic
kidney diseases caused by the diverse etiologies, as listed in
Table 1. Given the large number of distinct HDACs, most studies
in this field are currently conducted by using pan-HDACis
or class-specific HDACis. Thus, there is a need to identify
specific functions of each HDAC and to develop small molecule
inhibitors that can selectivelymodulate the activities of individual
HDAC isoforms. In addition, it is necessary to clarify the profile
of HDAC-modulated proteins in the setting of renal fibrosis
and other kidney diseases by using some novel techniques such
as proteomics to globally analyze protein lysine acetylation in
response to HDAC inhibition. Although numerous clinical trials
for application of HDACIs in tumors have been reported, there
is no clinical trial thus far to test the therapeutic effects of those
inhibitors in patients with CKD. Therefore, further investigation
of the mechanisms, efficacy and toxicity of HDACis in the
pre-clinical model of CKD will be helpful for initiating clinical
trials to assess the feasibility of HDACis in the treatment of this
disease in the future.
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